{"id":"W2514283099","doi":"10.1177/1756287216663073","title":"Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience","year":2016,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"FP7 Science in Society; Bristol-Myers Squibb","keywords":"Cabozantinib; Medicine; Sunitinib; Axitinib; Oncology; Metastasis; Renal cell carcinoma; Internal medicine; Targeted therapy; Tyrosine-kinase inhibitor; Cancer research; Vascular endothelial growth factor; Angiogenesis; Tyrosine kinase; Everolimus; Receptor tyrosine kinase; Cancer; Receptor; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001605575,0.0005592342,0.002064014,0.0008245297,0.0001444644,0.0008291431,0.001003973,0.0007057401,0.00293049],"category_scores_gemma":[0.002191435,0.0001508694,0.001182416,0.001413704,0.0002449095,0.0005291904,0.000324473,0.00106663,0.0004910892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005648168,"about_ca_system_score_gemma":0.001081699,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001006747,"about_ca_topic_score_gemma":0.002679738,"domain_scores_codex":[0.9996576,0.0001202737,0.00007325084,0.00003770839,0.00009157063,0.00001955947],"domain_scores_gemma":[0.9989743,0.0005953735,0.0001735009,0.00002190779,0.0001783413,0.00005649719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002692572,0.0001580825,0.0003904398,0.09743988,0.001787805,0.0001573895,0.00009305609,0.0005087337,0.001388452,0.001457923,0.01886203,0.8750637],"study_design_scores_gemma":[0.002891173,0.002946786,0.006492835,0.08405299,0.01144128,0.001788078,0.0002019966,0.0005031633,0.001816781,0.002606662,0.8851787,0.00007960808],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003545585,0.9988865,0.00003426688,0.0001262857,0.00005519236,0.00001334676,0.00002945519,0.000003026062,0.0004973281],"genre_scores_gemma":[0.003899274,0.9952925,0.000159492,0.0002693077,0.00006101427,0.00002259749,0.00006966294,0.000002371457,0.0002237973],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00293049,"threshold_uncertainty_score":0.009803474,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1681734959571597,"score_gpt":0.4580039289744441,"score_spread":0.2898304330172844,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}